Feifei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feifei Chen has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Lefu Lan
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China
18 shared publications - Jian Li
State Key Laboratory of Bioreactor Engineering, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
6 shared publications Qiao Cao
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China
6 shared publications- Wei Huang
Key Laboratory of Glyco-drug Research of Zhejiang Province, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China
6 shared publications Cai-Guang Yang
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China
5 shared publications- Dongliang Guan
Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery
5 shared publications
Latest Publications
- 15 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10993-11023
Discovery of New Teraryl γ-Lactam Derivatives as Potent Antibacterial Agents In Vitro and In Vivo through Dual Cell Wall–Membrane Inhibitions
Antimicrobial resistance threatens global public health, urgently requiring new antibiotics. Herein, we report a novel antibacterial scaffold with a 1,2,4-oxadiazole teraryl moiety and γ-lactam fragment via bacteria-based phenotypic screening. Diversified modifications of its four sites yielded 42 derivatives, and comprehensive SAR analysis against multidrug-resistant "superbugs" identified lead compound 8c. 8c exhibits excellent activity against drug-resistant Gram-positive bacteria (e.g., MRSA, VISA, VRE), 4-32-fold more potent than ciprofloxacin and meropenem. 8c shows rapid bactericidal activity, a low propensity to induce resistance, and a moderate safety profile. Mechanistically, 8c inhibits peptidoglycan biosynthesis by targeting the Lipid II cycle and disrupts membrane homeostasis via enhanced permeability and induced hyperpolarization, with this dual action validated by proteomic and lipidomic analyses. It also has excellent liver microsomal stability, favorable in vivo pharmacokinetics, and potent in vivo anti-MRSA efficacy. This novel scaffold is a promising addition to the antibiotic arsenal and warrants further development.
- 15 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10993-11023
Discovery of New Teraryl γ-Lactam Derivatives as Potent Antibacterial Agents In Vitro and In Vivo through Dual Cell Wall–Membrane Inhibitions
Antimicrobial resistance threatens global public health, urgently requiring new antibiotics. Herein, we report a novel antibacterial scaffold with a 1,2,4-oxadiazole teraryl moiety and γ-lactam fragment via bacteria-based phenotypic screening. Diversified modifications of its four sites yielded 42 derivatives, and comprehensive SAR analysis against multidrug-resistant "superbugs" identified lead compound 8c. 8c exhibits excellent activity against drug-resistant Gram-positive bacteria (e.g., MRSA, VISA, VRE), 4-32-fold more potent than ciprofloxacin and meropenem. 8c shows rapid bactericidal activity, a low propensity to induce resistance, and a moderate safety profile. Mechanistically, 8c inhibits peptidoglycan biosynthesis by targeting the Lipid II cycle and disrupts membrane homeostasis via enhanced permeability and induced hyperpolarization, with this dual action validated by proteomic and lipidomic analyses. It also has excellent liver microsomal stability, favorable in vivo pharmacokinetics, and potent in vivo anti-MRSA efficacy. This novel scaffold is a promising addition to the antibiotic arsenal and warrants further development.
- 12 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (8) , 8310-8329
Novel Aryl Sulfonium Modification on Vancomycin to Tackle MRSA and VRE In Vitro and In Vivo through Dual Enhanced Cell-Wall and Membrane Inhibition
Gram-positive superbugs resistant to methicillin and vancomycin pose a severe threat to global public health, urgently demanding novel therapeutic strategies. Herein, we rationally designed and synthesized vancomycin derivatives modified with diverse aryl sulfonium moieties to reactivate its antibacterial potency. By optimizing the sulfonium-based SAR, we got derivatives 2-3 orders of magnitude more active in vitro than vancomycin. Subsequently, preliminary toxicity evaluations for the optimal derivative, 7e, indicated a favorable therapeutic index, while pharmacokinetic assays revealed its good properties, suggesting great drug-like potential. Notably, 7e showed extremely potent in vivo protection efficacy by only a single-dose treatment in the challenging methicillin-resistant Staphylococcus aureus and VRE lethal sepsis mice models. Moreover, two independent and synergistic mechanisms of action were uncovered: membrane perturbation and enhanced cell wall biosynthesis inhibition. These findings revealed the unknown role of sulfonium strategy in vitro and in vivo and positioned 7e as a promising candidate for future development.
- 12 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (8) , 8310-8329
Novel Aryl Sulfonium Modification on Vancomycin to Tackle MRSA and VRE In Vitro and In Vivo through Dual Enhanced Cell-Wall and Membrane Inhibition
Gram-positive superbugs resistant to methicillin and vancomycin pose a severe threat to global public health, urgently demanding novel therapeutic strategies. Herein, we rationally designed and synthesized vancomycin derivatives modified with diverse aryl sulfonium moieties to reactivate its antibacterial potency. By optimizing the sulfonium-based SAR, we got derivatives 2-3 orders of magnitude more active in vitro than vancomycin. Subsequently, preliminary toxicity evaluations for the optimal derivative, 7e, indicated a favorable therapeutic index, while pharmacokinetic assays revealed its good properties, suggesting great drug-like potential. Notably, 7e showed extremely potent in vivo protection efficacy by only a single-dose treatment in the challenging methicillin-resistant Staphylococcus aureus and VRE lethal sepsis mice models. Moreover, two independent and synergistic mechanisms of action were uncovered: membrane perturbation and enhanced cell wall biosynthesis inhibition. These findings revealed the unknown role of sulfonium strategy in vitro and in vivo and positioned 7e as a promising candidate for future development.
- Open Access
- 13 February 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (3) , 1680-1695
Discovery of a novel polymyxin adjuvant against multidrug-resistant gram-negative bacteria through oxidative stress modulation
- 13 February 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (3) , 1680-1695
Open AccessDiscovery of a novel polymyxin adjuvant against multidrug-resistant gram-negative bacteria through oxidative stress modulation
- Open Access
- 30 July 2024
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 20 (7) , e1012425
Citrate serves as a signal molecule to modulate carbon metabolism and iron homeostasis in Staphylococcus aureus
Pathogenic bacteria’s metabolic adaptation for survival and proliferation within hosts is a crucial aspect of bacterial pathogenesis. Here, we demonstrate that citrate, the first intermediate of the tricarboxylic acid (TCA) cycle, plays a key role as a regulator of gene expression in Staphylococcus aureus. We show that citrate activates the transcriptional regulator CcpE and thus modulates the expression of numerous genes involved in key cellular pathways such as central carbon metabolism, iron uptake and the synthesis and export of virulence factors. Citrate can also suppress the transcriptional regulatory activity of ferric uptake regulator. Moreover, we determined that accumulated intracellular citrate, partly through the activation of CcpE, decreases the pathogenic potential of S. aureus in animal infection models. Therefore, citrate plays a pivotal role in coordinating carbon metabolism, iron homeostasis, and bacterial pathogenicity at the transcriptional level in S. aureus, going beyond its established role as a TCA cycle intermediate.
- 30 July 2024
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 20 (7) , e1012425
Open AccessCitrate serves as a signal molecule to modulate carbon metabolism and iron homeostasis in Staphylococcus aureus
Pathogenic bacteria’s metabolic adaptation for survival and proliferation within hosts is a crucial aspect of bacterial pathogenesis. Here, we demonstrate that citrate, the first intermediate of the tricarboxylic acid (TCA) cycle, plays a key role as a regulator of gene expression in Staphylococcus aureus. We show that citrate activates the transcriptional regulator CcpE and thus modulates the expression of numerous genes involved in key cellular pathways such as central carbon metabolism, iron uptake and the synthesis and export of virulence factors. Citrate can also suppress the transcriptional regulatory activity of ferric uptake regulator. Moreover, we determined that accumulated intracellular citrate, partly through the activation of CcpE, decreases the pathogenic potential of S. aureus in animal infection models. Therefore, citrate plays a pivotal role in coordinating carbon metabolism, iron homeostasis, and bacterial pathogenicity at the transcriptional level in S. aureus, going beyond its established role as a TCA cycle intermediate.
- 2 April 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (7) , 5958-5959
Correction to “A Vancomycin-Templated DNA-Encoded Library for Combating Drug-Resistant Bacteria”
- 2 April 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (7) , 5958-5959
Correction to “A Vancomycin-Templated DNA-Encoded Library for Combating Drug-Resistant Bacteria”
- 5 March 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (5) , 3778-3794
A Vancomycin-Templated DNA-Encoded Library for Combating Drug-Resistant Bacteria
It is an urgent need to tackle the global crisis of multidrug-resistant bacterial infections. We report here an innovative strategy for large-scale screening of new antibacterial agents using a whole bacteria-based DNA-encoded library (DEL) of vancomycin derivatives via peripheral modifications. A bacterial binding affinity assay was established to select the modification fragments in high-affinity compounds. The optimal resynthesized derivatives demonstrated excellently enhanced activity against various resistant bacterial strains and provided useful structures for vancomycin derivatization. This work presents the new concept in a natural product-templated DEL and in antibiotic discovery through bacterial affinity screening, which promotes the fight against drug-resistant bacteria.
- 5 March 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (5) , 3778-3794
A Vancomycin-Templated DNA-Encoded Library for Combating Drug-Resistant Bacteria
It is an urgent need to tackle the global crisis of multidrug-resistant bacterial infections. We report here an innovative strategy for large-scale screening of new antibacterial agents using a whole bacteria-based DNA-encoded library (DEL) of vancomycin derivatives via peripheral modifications. A bacterial binding affinity assay was established to select the modification fragments in high-affinity compounds. The optimal resynthesized derivatives demonstrated excellently enhanced activity against various resistant bacterial strains and provided useful structures for vancomycin derivatization. This work presents the new concept in a natural product-templated DEL and in antibiotic discovery through bacterial affinity screening, which promotes the fight against drug-resistant bacteria.
- Open Access
- 2 May 2023
- Published by Wiley in ChemMedChem
- Vol. 18 (9)
Front Cover: Single Modification at the N‐Terminus of Norvancomycin to Combat Drug‐Resistant Gram‐Positive Bacteria (ChemMedChem 9/2023)
- 2 May 2023
- Published by Wiley in ChemMedChem
- Vol. 18 (9)
Open AccessFront Cover: Single Modification at the N‐Terminus of Norvancomycin to Combat Drug‐Resistant Gram‐Positive Bacteria (ChemMedChem 9/2023)
- Open Access
- 22 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Modulation of MRSA virulence gene expression by the wall teichoic acid enzyme TarO
Phenol-soluble modulins (PSMs) and Staphylococcal protein A (SpA) are key virulence determinants for community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), an important human pathogen that causes a wide range of diseases. Here, using chemical and genetic approaches, we show that inhibition of TarO, the first enzyme in the wall teichoic acid (WTA) biosynthetic pathway, decreases the expression of genes encoding PSMs and SpA in the prototypical CA-MRSA strain USA300 LAC. Mechanistically, these effects are linked to the activation of VraRS two-component system that directly represses the expression of accessory gene regulator (agr) locus and spa. The activation of VraRS was due in part to the loss of the functional integrity of penicillin-binding protein 2 (PBP2) in a PBP2a-dependent manner. TarO inhibition can also activate VraRS in a manner independent of PBP2a. We provide multiple lines of evidence that accumulation of lipid-linked peptidoglycan precursors is a trigger for the activation of VraRS. In sum, our results reveal that WTA biosynthesis plays an important role in the regulation of virulence gene expression in CA-MRSA, underlining TarO as an attractive target for anti-virulence therapy. Our data also suggest that acquisition of PBP2a-encoding mecA gene can impart an additional regulatory layer for the modulation of key signaling pathways in S. aureus.
- 22 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Open AccessModulation of MRSA virulence gene expression by the wall teichoic acid enzyme TarO
Phenol-soluble modulins (PSMs) and Staphylococcal protein A (SpA) are key virulence determinants for community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), an important human pathogen that causes a wide range of diseases. Here, using chemical and genetic approaches, we show that inhibition of TarO, the first enzyme in the wall teichoic acid (WTA) biosynthetic pathway, decreases the expression of genes encoding PSMs and SpA in the prototypical CA-MRSA strain USA300 LAC. Mechanistically, these effects are linked to the activation of VraRS two-component system that directly represses the expression of accessory gene regulator (agr) locus and spa. The activation of VraRS was due in part to the loss of the functional integrity of penicillin-binding protein 2 (PBP2) in a PBP2a-dependent manner. TarO inhibition can also activate VraRS in a manner independent of PBP2a. We provide multiple lines of evidence that accumulation of lipid-linked peptidoglycan precursors is a trigger for the activation of VraRS. In sum, our results reveal that WTA biosynthesis plays an important role in the regulation of virulence gene expression in CA-MRSA, underlining TarO as an attractive target for anti-virulence therapy. Our data also suggest that acquisition of PBP2a-encoding mecA gene can impart an additional regulatory layer for the modulation of key signaling pathways in S. aureus.
- Open Access
- 10 February 2023
- Published by Taylor & Francis in Virulence
- Vol. 14 (1) , 2171641
The enzyme activity of sortase A is regulated by phosphorylation in Staphylococcus aureus
In many Gram-positive bacteria, the transpeptidase enzyme sortase A (SrtA) anchors surface proteins to cell wall and plays a critical role in the bacterial pathogenesis. Here, we show that in Staphylococcus aureus, an important human pathogen, the SrtA is phosphorylated by serine/threonine protein kinase Stk1. S. aureus SrtA can also be phosphorylated by small-molecule phosphodonor acetyl phosphate (AcP) in vitro. We determined that various amino acid residues of S. aureus SrtA are subject to phosphorylation, primarily on its catalytic site residue cysteine-184 in the context of a bacterial cell lysate. Both Stk1 and AcP-mediated phosphorylation inhibited the enzyme activity of SrtA in vitro. Consequently, deletion of gene (i.e. stp1) encoding serine/threonine phosphatase Stp1, the corresponding phosphatase of Stk1, caused an increase in the phosphorylation level of SrtA. The stp1 deletion mutant mimicked the phenotypic traits of srtA deletion mutant (i.e. attenuated growth where either hemoglobin or heme as a sole iron source and reduced liver infections in a mouse model of systemic infection). Importantly, the phenotypic defects of the stp1 deletion mutant can be alleviated by overexpressing srtA. Taken together, our finding suggests that phosphorylation plays an important role in modulating the activity of SrtA in S. aureus.
- 10 February 2023
- Published by Taylor & Francis in Virulence
- Vol. 14 (1) , 2171641
Open AccessThe enzyme activity of sortase A is regulated by phosphorylation in Staphylococcus aureus
In many Gram-positive bacteria, the transpeptidase enzyme sortase A (SrtA) anchors surface proteins to cell wall and plays a critical role in the bacterial pathogenesis. Here, we show that in Staphylococcus aureus, an important human pathogen, the SrtA is phosphorylated by serine/threonine protein kinase Stk1. S. aureus SrtA can also be phosphorylated by small-molecule phosphodonor acetyl phosphate (AcP) in vitro. We determined that various amino acid residues of S. aureus SrtA are subject to phosphorylation, primarily on its catalytic site residue cysteine-184 in the context of a bacterial cell lysate. Both Stk1 and AcP-mediated phosphorylation inhibited the enzyme activity of SrtA in vitro. Consequently, deletion of gene (i.e. stp1) encoding serine/threonine phosphatase Stp1, the corresponding phosphatase of Stk1, caused an increase in the phosphorylation level of SrtA. The stp1 deletion mutant mimicked the phenotypic traits of srtA deletion mutant (i.e. attenuated growth where either hemoglobin or heme as a sole iron source and reduced liver infections in a mouse model of systemic infection). Importantly, the phenotypic defects of the stp1 deletion mutant can be alleviated by overexpressing srtA. Taken together, our finding suggests that phosphorylation plays an important role in modulating the activity of SrtA in S. aureus.
- Open Access
- 7 July 2022
- Published by Springer Nature in Research Square
Chemical genetics unveils WTA/PBP2a-PBP2/VraRS as a regulatory axis for virulence gene expression in CA-MRSA
Phenol-soluble modulins (PSMs) and Staphylococcal protein A (SpA) are key virulence determinants for community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Here, using chemical and genetic approaches, we show that inhibition of TarO, the first enzyme in the wall teichoic acid (WTA) biosynthetic pathway, decreases the expression of genes encoding PSMs and SpA in the prototypical CA-MRSA strain USA300 LAC. Mechanistically, these effects are linked to the activation of VraRS two-component system that directly represses the expression of accessory gene regulator (agr) locus and spa. The activation of VraRS was due, at least in part, to the loss of the functional integrity of penicillin-binding protein 2 (PBP2) in a PBP2a-dependent manner. We provide multiple lines of evidence that the accumulation of lipid-linked peptidoglycan precursors is a trigger for the activation of VraRS. In sum, our data reveal an unprecedented and important role for WTA biosynthesis in the regulation of virulence gene expression in CA-MRSA, underlining that acquisition of PBP2a-encoding mecA gene can impart an additional regulatory layer for the modulation of key signaling pathways (e.g., VraRS and agr) in S. aureus.
- 7 July 2022
- Published by Springer Nature in Research Square
Open AccessChemical genetics unveils WTA/PBP2a-PBP2/VraRS as a regulatory axis for virulence gene expression in CA-MRSA
Phenol-soluble modulins (PSMs) and Staphylococcal protein A (SpA) are key virulence determinants for community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Here, using chemical and genetic approaches, we show that inhibition of TarO, the first enzyme in the wall teichoic acid (WTA) biosynthetic pathway, decreases the expression of genes encoding PSMs and SpA in the prototypical CA-MRSA strain USA300 LAC. Mechanistically, these effects are linked to the activation of VraRS two-component system that directly represses the expression of accessory gene regulator (agr) locus and spa. The activation of VraRS was due, at least in part, to the loss of the functional integrity of penicillin-binding protein 2 (PBP2) in a PBP2a-dependent manner. We provide multiple lines of evidence that the accumulation of lipid-linked peptidoglycan precursors is a trigger for the activation of VraRS. In sum, our data reveal an unprecedented and important role for WTA biosynthesis in the regulation of virulence gene expression in CA-MRSA, underlining that acquisition of PBP2a-encoding mecA gene can impart an additional regulatory layer for the modulation of key signaling pathways (e.g., VraRS and agr) in S. aureus.